• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大洋洲多发性硬化症(MS)的患病率:系统评价和荟萃分析。

The prevalence of multiple sclerosis (MS) in Oceania, a systematic review, and meta-analysis.

机构信息

Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

Department of Immunology, Isfahan University of Medical Science, Isfahan, Iran.

出版信息

Neurol Sci. 2024 Jan;45(1):75-82. doi: 10.1007/s10072-023-07057-4. Epub 2023 Sep 8.

DOI:10.1007/s10072-023-07057-4
PMID:37682389
Abstract

BACKGROUND

Oceania is a continent, covering more than 8 million km, with a population of more than 44 million people. In different countries landing in Oceania, various prevalence of MS has been reported, so we designed this systematic review and meta-analysis to estimate the pooled prevalence of MS in Oceania.

METHODS

We systematically searched PubMed, Scopus, EMBASE, Web of Science, and Google Scholar. We also searched references of included studies, and conference abstracts. The search was done on January 1, 2023, by two independent researchers. We extracted the name of the first author, country, publication year, prevalence period, number of study participants, total female and male population, disease duration, type of MS, mean duration of the disease, mean age at disease onset, mean Expanded Disability Status Scale (EDSS), and total female and male patients with MS.

RESULTS

A literature search revealed 81,044 records; after deleting duplicates, 38,260 records remained. One hundred and six full texts were evaluated, and finally, seventeen studies remained for systematic review. Most studies were done in Newcastle; eight studies were done in 1961, 8 in 1981, 2 in 1996, and 2 in 2001. In all other years, only one study was done. The pooled prevalence of MS in 1961 in Oceania was estimated as 19.85/100,000 (I=70.3%, p=0.001). The pooled prevalence of MS in 1981 in Oceania was estimated as 39.07/100,000 (I =88%, p=0.001).

CONCLUSIONS

The result of this systematic review and meta-analysis shows that the prevalence of MS has increased dramatically during the timespan in Oceania.

摘要

背景

大洋洲是一个大陆,面积超过 800 万平方公里,人口超过 4400 万。在大洋洲的不同国家,报道了各种多发性硬化症的流行率,因此我们设计了这项系统回顾和荟萃分析,以估计大洋洲多发性硬化症的总体流行率。

方法

我们系统地检索了 PubMed、Scopus、EMBASE、Web of Science 和 Google Scholar。我们还检索了纳入研究的参考文献和会议摘要。搜索于 2023 年 1 月 1 日由两名独立研究人员进行。我们提取了第一作者的姓名、国家、出版年份、流行期、研究参与者人数、总女性和男性人口、疾病持续时间、多发性硬化症类型、疾病平均持续时间、疾病平均发病年龄、平均扩展残疾状况量表(EDSS)以及多发性硬化症的总女性和男性患者人数。

结果

文献检索显示有 81044 条记录;删除重复项后,仍有 38260 条记录。评估了 106 篇全文,最终有 17 项研究纳入系统评价。大多数研究是在纽卡斯尔进行的;8 项研究于 1961 年进行,8 项研究于 1981 年进行,2 项研究于 1996 年进行,2 项研究于 2001 年进行。在其他所有年份,仅进行了一项研究。1961 年大洋洲多发性硬化症的总体流行率估计为 19.85/100000(I=70.3%,p=0.001)。1981 年大洋洲多发性硬化症的总体流行率估计为 39.07/100000(I=88%,p=0.001)。

结论

这项系统回顾和荟萃分析的结果表明,在大洋洲的这段时间内,多发性硬化症的流行率显著增加。

相似文献

1
The prevalence of multiple sclerosis (MS) in Oceania, a systematic review, and meta-analysis.大洋洲多发性硬化症(MS)的患病率:系统评价和荟萃分析。
Neurol Sci. 2024 Jan;45(1):75-82. doi: 10.1007/s10072-023-07057-4. Epub 2023 Sep 8.
2
Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis.**标题**:用于多发性硬化症(MS)患者步态失衡的苯丁胺:系统评价和荟萃分析。
Neurol Sci. 2023 Sep;44(9):3059-3069. doi: 10.1007/s10072-023-06795-9. Epub 2023 Apr 14.
3
Multiple sclerosis epidemiology in Asia and Oceania; A systematic review and meta-analysis.亚洲和大洋州多发性硬化症的流行病学; 系统评价和荟萃分析。
Mult Scler Relat Disord. 2021 Sep;54:103119. doi: 10.1016/j.msard.2021.103119. Epub 2021 Jun 30.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
6
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.对首次出现提示多发性硬化症临床发作的患者使用疾病修饰药物进行治疗。
Cochrane Database Syst Rev. 2017 Apr 25;4(4):CD012200. doi: 10.1002/14651858.CD012200.pub2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
8
The prevalence of restless legs syndrome (RLS) in patients with multiple sclerosis (MS): a systematic review and meta-analysis-an update.多发性硬化症(MS)患者中不宁腿综合征(RLS)的患病率:系统评价与荟萃分析——最新进展
Neurol Sci. 2023 Jan;44(1):67-82. doi: 10.1007/s10072-022-06364-6. Epub 2022 Sep 5.
9
Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis.多发性硬化症(MS)患者接受芬戈莫德治疗后的癌症发病率:系统评价和荟萃分析。
Mult Scler Relat Disord. 2022 Mar;59:103680. doi: 10.1016/j.msard.2022.103680. Epub 2022 Feb 9.
10
Prognosis of adults and children following a first unprovoked seizure.首次无诱因发作后成人和儿童的预后。
Cochrane Database Syst Rev. 2023 Jan 23;1(1):CD013847. doi: 10.1002/14651858.CD013847.pub2.

引用本文的文献

1
Characteristics and correlations of sleep disorders in patients with relapsing-remitting multiple sclerosis in China: a cross-sectional study.中国复发缓解型多发性硬化症患者睡眠障碍的特征及相关性:一项横断面研究
Front Neurol. 2025 Jul 17;16:1608802. doi: 10.3389/fneur.2025.1608802. eCollection 2025.

本文引用的文献

1
Incidence and prevalence of multiple sclerosis in China and other Asian countries.中国和其他亚洲国家多发性硬化症的发病率和患病率。
Neurologia (Engl Ed). 2023 Apr;38(3):159-172. doi: 10.1016/j.nrleng.2020.07.022.
2
Increasing Incidence and Male to Female Sex Ratio of Multiple Sclerosis in Tehran, Iran: A Population-Based Study.伊朗德黑兰多发性硬化症发病率上升及男女比例变化:一项基于人群的研究
Iran J Public Health. 2022 May;51(5):1193-1194. doi: 10.18502/ijph.v51i5.9439.
3
Prevalence of multiple sclerosis (MS) in Iran: a systematic review and meta-analysis.
伊朗多发性硬化症(MS)的患病率:系统评价和荟萃分析。
Neurol Sci. 2022 Jan;43(1):233-241. doi: 10.1007/s10072-021-05750-w. Epub 2021 Nov 17.
4
Multiple Sclerosis in the Asia Pacific Region: A Systematic Review of a Neglected Neurological Disease.亚太地区的多发性硬化症:对一种被忽视的神经系统疾病的系统评价
Front Neurol. 2018 Jun 8;9:432. doi: 10.3389/fneur.2018.00432. eCollection 2018.
5
Comparison of serum vitamin D level in multiple sclerosis patients, their siblings, and healthy controls.多发性硬化症患者、其兄弟姐妹及健康对照者的血清维生素D水平比较。
Iran J Neurol. 2015 Apr 4;14(2):81-5.
6
Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity.《2013年多发性硬化症图谱:一个全球范围不断扩大且存在广泛不平等现象的问题》
Neurology. 2014 Sep 9;83(11):1022-4. doi: 10.1212/WNL.0000000000000768.
7
Fatigue in multiple sclerosis: relationship with disease duration, physical disability, disease pattern, age and sex.多发性硬化症中的疲劳:与疾病持续时间、身体残疾、疾病类型、年龄和性别有关。
Acta Neurol Belg. 2013 Dec;113(4):411-4. doi: 10.1007/s13760-013-0198-2. Epub 2013 Apr 25.
8
Sex-specific environmental influences affecting MS development.影响多发性硬化症发病的性别特异性环境影响。
Clin Immunol. 2013 Nov;149(2):176-81. doi: 10.1016/j.clim.2013.02.006. Epub 2013 Feb 21.
9
Trends in the epidemiology of multiple sclerosis in Greater Hobart, Tasmania: 1951 to 2009.塔斯马尼亚州霍巴特大都市区多发性硬化症的流行病学趋势:1951 年至 2009 年。
J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):180-7. doi: 10.1136/jnnp.2010.215186. Epub 2010 Nov 20.
10
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.纽卡斯尔-渥太华量表在荟萃分析中评估非随机研究质量的批判性评价。
Eur J Epidemiol. 2010 Sep;25(9):603-5. doi: 10.1007/s10654-010-9491-z. Epub 2010 Jul 22.